137.45
price down icon0.98%   -1.36
after-market Handel nachbörslich: 137.69 0.24 +0.17%
loading
Schlusskurs vom Vortag:
$138.81
Offen:
$138.19
24-Stunden-Volumen:
1.20M
Relative Volume:
1.75
Marktkapitalisierung:
$8.35B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
19.36
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
-1.98%
1M Leistung:
+11.29%
6M Leistung:
+28.34%
1J Leistung:
+16.95%
1-Tages-Spanne:
Value
$136.48
$140.27
1-Wochen-Bereich:
Value
$135.36
$142.93
52-Wochen-Spanne:
Value
$99.06
$148.06

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name
Firmenname
Jazz Pharmaceuticals Plc
Name
Telefon
353-1-634-7800
Name
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Name
Mitarbeiter
2,800
Name
Twitter
@jazzpharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
JAZZ's Discussions on Twitter

Vergleichen Sie JAZZ mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
JAZZ
Jazz Pharmaceuticals Plc
137.45 8.35B 3.99B 463.16M 1.10B 7.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.01 128.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
744.83 81.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
571.00 34.69B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
233.07 30.17B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.66 26.02B 3.32B -860.46M -1.04B -8.32

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-07 Hochstufung UBS Neutral → Buy
2025-02-26 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-02-13 Hochstufung Wells Fargo Equal Weight → Overweight
2024-12-12 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-06-05 Eingeleitet Goldman Buy
2024-01-03 Eingeleitet Robert W. Baird Outperform
2023-11-27 Herabstufung UBS Buy → Neutral
2023-09-29 Eingeleitet Raymond James Mkt Perform
2023-06-12 Fortgesetzt Wells Fargo Equal Weight
2022-12-09 Hochstufung Goldman Neutral → Buy
2022-06-14 Eingeleitet UBS Buy
2022-04-06 Herabstufung Goldman Buy → Neutral
2021-11-19 Fortgesetzt Goldman Buy
2021-10-07 Fortgesetzt Jefferies Buy
2021-10-05 Eingeleitet Citigroup Buy
2021-09-23 Eingeleitet Needham Buy
2021-05-19 Fortgesetzt JP Morgan Overweight
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2021-02-05 Bestätigt H.C. Wainwright Buy
2021-02-03 Hochstufung Piper Sandler Neutral → Overweight
2021-01-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-12-16 Eingeleitet UBS Buy
2020-11-03 Bestätigt H.C. Wainwright Buy
2020-10-09 Bestätigt H.C. Wainwright Buy
2020-09-14 Herabstufung Goldman Neutral → Sell
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-08-06 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-07-28 Hochstufung Wolfe Research Peer Perform → Outperform
2020-07-23 Hochstufung H.C. Wainwright Neutral → Buy
2020-04-06 Eingeleitet Jefferies Buy
2020-03-12 Hochstufung Bernstein Mkt Perform → Outperform
2020-01-08 Eingeleitet Goldman Neutral
2019-08-21 Herabstufung Piper Jaffray Overweight → Neutral
2019-06-11 Eingeleitet Barclays Overweight
2019-03-20 Eingeleitet SunTrust Buy
2018-12-14 Eingeleitet Wolfe Research Peer Perform
2018-11-08 Bestätigt B. Riley FBR Buy
2018-08-08 Bestätigt Stifel Buy
2018-07-11 Herabstufung Morgan Stanley Overweight → Equal-Weight
2018-03-23 Bestätigt H.C. Wainwright Neutral
2018-03-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
Alle ansehen

Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten

pulisher
02:28 AM

HC Wainwright Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World

02:28 AM
pulisher
Mar 10, 2025

Insider Sell: Bruce Cozadd Sells 6,500 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus.com

Mar 10, 2025
pulisher
Mar 10, 2025

DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga India

Mar 10, 2025
pulisher
Mar 10, 2025

Victory Capital Management Inc. Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS Group - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Robert Iannone Sells 7,080 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Morgan Stanley Reiterates “Overweight” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Truist Financial Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $230.00 - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

UBS Upgrades Jazz Pharmaceuticals (JAZZ) - Nasdaq

Mar 07, 2025
pulisher
Mar 07, 2025

Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145 - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

UBS raises Jazz Pharmaceuticals stock rating to Buy, target to $179 By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells 4,813 Shares of Stock - MarketBeat

Mar 07, 2025
pulisher
Mar 07, 2025

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq

Mar 07, 2025
pulisher
Mar 06, 2025

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

Jazz Pharmaceuticals at TD Cowen Conference: Strategic Growth in Focus By Investing.com - Investing.com UK

Mar 06, 2025
pulisher
Mar 06, 2025

Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart

Mar 06, 2025
pulisher
Mar 06, 2025

Truist lifts Jazz Pharma stock target to $230 on promising pipeline - Investing.com UK

Mar 06, 2025
pulisher
Mar 06, 2025

Truist Raises Price Target on Jazz Pharmaceuticals to $230 From $220, Keeps Buy Rating - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Jazz Pharma to acquire Chimerix for ~$935M in cash - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Jazz Seeks To Augment Rare Cancer Portfolio With Chimerx Buyout - News & Insights

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to acquire Chimerix for $935 million By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix brings a rare cancer drug to the $935M Jazz party - BioWorld Online

Mar 05, 2025
pulisher
Mar 05, 2025

3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX, - Barchart

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz - BioCentury

Mar 05, 2025
pulisher
Mar 05, 2025

3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX, - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts - Benzinga

Mar 05, 2025
pulisher
Mar 05, 2025

Executive VP & Chief Legal Officer Neena Patil Sold A Bunch Of Shares In Jazz Pharmaceuticals - Simply Wall St

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Buys ChimerixA Good Deal To Make With Major Approval Catalyst In Play - Seeking Alpha

Mar 05, 2025
pulisher
Mar 05, 2025

3 Firms Build Jazz Pharmaceuticals' $935M Chimerix Buy - Law360

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals bids for Chimerix in $935m deal - Pharmaceutical Technology

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz expands in oncology with $935M deal for Chimerix - BioPharma Dive

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals plc entered into a definitive agreement to acquire Chimerix, Inc. for approximately $930 million. - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharma aims to boost cancer drug pipeline with $935 million buyoutSan Francisco Business Times - The Business Journals

Mar 05, 2025
pulisher
Mar 05, 2025

Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals Acquires Chimerix In $935 Million Deal - Finimize

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to buy Chimerix for $935 million - MLex

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to Acquire Chimerix for $935M - Contract Pharma

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals buys Chimerix for $935 million - Green Market Report

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals To Acquire Chimerix For $935 Million - citybiz

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Benzinga

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to Acquire Chimerix in $935M Deal - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to acquire Chimerix for $935 million - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to buy Chimerix for $935 million -March 05, 2025 at 07:28 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix stock gains on Jazz Pharma bid (JAZZ:NASDAQ) - Seeking Alpha

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to Buy Chimerix for Roughly $935 Million -March 05, 2025 at 07:09 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

JAZZ (JAZZ) to Acquire Chimerix (CMRX) for $8.55/sh Cash - StreetInsider.com

Mar 05, 2025

Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$35.96
price up icon 0.98%
$21.98
price down icon 8.97%
$32.75
price down icon 0.79%
$317.87
price up icon 0.62%
$105.35
price down icon 3.15%
biotechnology ONC
$242.66
price down icon 1.78%
Kapitalisierung:     |  Volumen (24h):